Background: Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous reports suggest that these changes may be reversible after discontinuation of TDF.
INTRODUCTION
Randomized trials have demonstrated that pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate (TDF) or coformulated TDF with emtricitabine (TDF/FTC, Truvada) prevents HIV acquisition. [1] [2] [3] [4] [5] [6] In HIV treatment, TDFbased therapy has been associated with decreases in bone mineral density (BMD) with unclear clinical significance 7 ; some studies have found that TDF is associated with increased fracture risk, whereas others have not. [8] [9] [10] [11] [12] HIV therapy switch studies have found that substitution of TDF leads to some BMD recovery, suggesting that BMD changes are reversible. [13] [14] [15] Trials of TDF-based PrEP have documented BMD decreases of 0.5%-1.5% with no clear excess fracture signal. [16] [17] [18] [19] Bone toxicity has partially motivated the testing of alternative PrEP agents. Recently, the MTN 003B PrEP trial 19 found reversible BMD changes after withdrawal of TDF-PrEP in a cohort of young African women. We examine the trajectory of BMD changes through extended follow-up of the iPrEx studies. 1, 20 
METHODS

Study Design
We analyzed an opt-in substudy nested in a placebocontrolled randomized clinical trial (iPrEx study) of daily oral TDF/FTC for PrEP in men who have sex with men and transgender women (MSM/TW). The bone and metabolic substudy enrolled at 7 of 11 iPrEx sites-in 5 cities (Cape Town, South Africa; Chiang Mai, Thailand; Lima, Peru; Rio de Janiero, Brazil; San Francisco, USA) with a target enrollment of 500 and achieved enrollment of 498 HIVuninfected volunteers. The study conduct was consistent with the Declaration of Helsinki; the protocol was approved by the ethics committee at each site and all participants provided written informed consent.
Participants underwent dual X-ray absorptiometry (DXA) to quantify bone mineral density (BMD) in the hip and spine at enrollment and every 24 weeks until study drug stop (stop visit) and 24 weeks after discontinuation of study drug (post-stop visit). The scans were performed using the same protocol across sites. The full methods and results for iPrEx have been published previously 1, 20 as well as for the bone substudy. 16 After a gap in participation, volunteers were invited to enroll in the iPrEx openlabel extension (OLE), which offered TDF/FTC for up to 18 months. The population and procedures for iPrEx OLE have been reported previously. 20 DXA participants from iPrEx were scanned at entry into iPrEx OLE. Randomized study drug was ended for iPrEx participants in August 2010 and enrollment in iPrEx OLE occurred between June 2011 and June 2012.
Drug Levels
All DXA participants randomized to TDF/FTC underwent drug-level testing for tenofovir and its metabolites in samples were collected during the clinical trial. 21 Of particular interest are levels of tenofovir diphosphate (TFV-DP) in viably cryopreserved peripheral blood mononuclear cells (vPBMCs) collected at the week 24 visit; these levels showed a linear association with peak loss of BMD in TDF/FTC participants. 16 We dichotomized these levels as TFV-DP ,16 vs. TFV-DP $16 fmol per million vPBMCs, a level which is associated with a 90% reduction in HIV incidence 21 and use of approximately 2-3 tablets per week on average. 21 
Statistical Analysis
We examined BMD levels at 5 time points: iPrEx enrollment, iPrEx week 24, the iPrEx stop visit, 24 weeks post-stop, and at OLE enrollment. We compared BMD for those on placebo versus TDF/FTC randomization and then further by the week 24 TFV-DP levels in PBMCs (TFV-DP ,16 vs. TFV-DP $16).
Average percentage BMD changes from baseline in hip and spine were compared across groups (TDF/FTC vs. placebo and TFV-DP ,16, TFV-DP $16 vs. placebo) by a linear mixed-effects model with an unstructured covariance matrix. 22 We examined consistency of this effect across age, baseline BMD Z-score, sex identity and duration on randomized drug.
The annual rate of BMD change (relative to baseline BMD) after the stop visit comparing TDF/FTC versus. placebo and TFV-DP ,16, TFV-DP $16 versus. placebo used a mixed effects model with random slopes and intercepts 22 and allowing for interactions of slope and intercept with randomization/drug exposure in the fixed model.
To address missing DXA scans (29% missed a poststop and 42% have no OLE DXA), 200 multiple imputations 23 of the BMD values based on values at baseline, week 24, and the stop visit as well as age, race, site, height, weight, lean body mass, and date of stop scan were analyzed with the "mi" package in Stata. Demographics of those with complete and missing DXA scans were compared using the t test for continuous variables and Fisher exact test for categorical variables. All analyses were performed in Stata 14. Of the 498 participants, 24-week post-stop scans were available in 352 (71%), and at OLE enrollment in 289 (58%). All participants have a stop scan which was after baseline in 493 (99%) at a median of 64 weeks on study (IQR: 41-87).
RESULTS
Available Scans Baseline Characteristics
Baseline characteristics (at iPrEx enrollment) varied slightly across availability of BMD scans at the 24-week poststop visit and OLE enrollment (Supplemental Digital Content Table 1 , http://links.lww.com/QAI/B52). Older participants were statistically significantly more likely to be scanned after drug stop (P , 0.001, 24-week post-stop; P = 0.01, OLE entry); however, median age of participants with scans at 24-week post-stop (median: 25, IQR: 21-34) and OLE enrollment (median: 26 IQR: 21-34) was similar to the overall DXA population (median: 25, IQR: 21-33). Weeks on study medication was also higher in those with post-stop and OLE entry scan (P , 0.001 both comparisons) reflecting those who discontinued study early were less likely to return for post-drug visits or enroll in OLE. The proportion with post-stop and OLE scans varied by enrolling site ranging from 40% to 76% (P = 0.05) and 26%-67% (P , 0.001), but there was no difference by randomized arm. Among TDF/ FTC participants with TFV-DP ,16 fmol, 76% had 24-week scans compared with 80% of those with TFV-DP $16 (P = 0.48); at OLE entry, it was 55% versus 69% (P = 0.04) had scans completed at OLE entry by the TFV-DP grouping, respectively. Overall, older participants, more adherent participants, and those who remained on study drug longer were more likely to be retained for scans after study drug discontinuation. Figure 1A and Figure 2A 
Post-stop Changes in BMD
Sensitivity Analyses
To examine the effect of attrition, multiple imputations were used to infer missing scans based on baseline, week 24, and stop as well as age, race, site, height, weight, lean body mass, and date of stop scan. The results were substantially similar and appear in Figure 1B and Figure 2B for hip and spine, respectively.
We examined consistency of BMD effects during and after PrEP by comparing subgroups by age (,25 year at enrollment vs. $25 years at enrollment, Figures 1 and 2 panels (c) and (d), respectively), baseline BMD Z-score (Zscore , 21 at enrollment vs. Z-score $1, panels (e) and (f), respectively), and duration of randomized study treatment in iPrEx (,1 year of study treatment vs. $1 year, panels (g) and (h), respectively). The graphs suggest consistent evidence across subgroups of bone loss on study with clear trajectory for recovery at or above baseline levels. Of note, participants aged $25 years with TFV-DP $16 at week 24 have BMD in spine (Fig. 2D) 0.67% below baseline at OLE entry (95% CI: 21.94% to +0.60%); however, the change is not significantly different from placebo (P = 0.10). There is no significant association between TDF/FTC duration and recovery in hip or spine BMD. Recovery did vary by site but our sites are heterogeneous in adherence, participant demographics, and scan completion, complicating interpretation.
For the 7 trans woman identified, participants with TFV-DP $16, changes were +0.68% (95% CI: 21.00% to +2.37%) at the stop scan and +3.33% (95% CI: +0.98% to +5.68%) at OLE entry in the hip and 21.35% (295% CI: 23.19% to +0.49%) at the stop scan and 3.14% (95% CI: 20.64% to +6.92%) at OLE entry in the spine. We saw no evidence of an interaction between treatment and sex identity of BMD recovery (P = 0.86). There was also consistent evidence of recovery stratifying the active arm using 25 fmol/10 6 vPBMC (consistent with at least 4 pills per week of TDF/FTC) at week 24.
DISCUSSION
We reported extended off-drug BMD follow-up in a geographically and demographically diverse sample of MSM/TW. We document increases in BMD after drug discontinuation in TDF/FTC-adherent participants of approximately 1.0% per year relative to placebo (Hip: Placebo, 0.19% per year vs. TDF-DP $16, 1.13% per year; Spine: Placebo, 0.74% per year vs. TDF-DP $16, 1.81 per/year). This is consistent with the observation in MTN003B that TDF-PrEP-adherent young African women also experienced return to baseline BMD over the years after PrEP discontinuation. 19 Both studies suggest that full recovery is not evident by 24 weeks after discontinuation but is evident after stopping oral FTC/TDF PrEP for 48-79 weeks.
BMD recovery appears consistent across age, duration of PrEP, and baseline BMD. However, our numbers are modest overall and our power is limited to examine recovery in key PrEP populations including those who have not reached peak bone mass, those over 50, people who cycle on/off PrEP, "on demand" users or who use it for periods longer than our cohort. Our numbers are particularly small for TW participants (;7 trans women in the active arm of the substudy with evidence of high adherence); we previously reported that trans women tended to have less BMD decreases during PrEP 24 possibly because of the bone protective effects of feminizing hormones or lower adherence.
We used multiple imputations to account for missing scans. This approach is valid even with a large proportion of missing data. Its validity requires the missing at random assumption 23 that differences in missing and nonmissing scan can be explained by variables used for constructing imputations. This assumption can never be fully verified.
A reviewer asked us to assess recovery of phosphorous and estimated glomerular filtration rate. The former was not reduced and hence not recovered. We previously documented the recovery of eGFR after stopping TDF/FTC. 25 This study suggests that discontinuation of TDF/FTC for PrEP will lead to BMD recovery to levels expected in the absence of PrEP in populations of MSM/TW.
